Hong‐Bin Fang

ORCID: 0000-0002-6173-9082
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Statistical Methods and Inference
  • Statistical Methods in Clinical Trials
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Optimal Experimental Design Methods
  • Multiple Myeloma Research and Treatments
  • MicroRNA in disease regulation
  • Statistical Methods and Bayesian Inference
  • Cancer-related molecular mechanisms research
  • Histone Deacetylase Inhibitors Research
  • Statistical Distribution Estimation and Applications
  • RNA modifications and cancer
  • Hematopoietic Stem Cell Transplantation
  • Cancer, Lipids, and Metabolism
  • Computational Drug Discovery Methods
  • Bayesian Methods and Mixture Models
  • Advanced Statistical Methods and Models
  • Gene expression and cancer classification
  • RNA Interference and Gene Delivery
  • Ubiquitin and proteasome pathways
  • Click Chemistry and Applications
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Metabolomics and Mass Spectrometry Studies
  • Renal Transplantation Outcomes and Treatments

Shenzhen University
2023-2025

First Affiliated Hospital of Henan University
2023-2025

Georgetown University
2015-2024

Georgetown University Medical Center
2015-2024

University of Maryland, Baltimore
2009-2023

Shenzhen University Health Science Center
2023

University of Mary
2023

University of Pennsylvania
2014

Oncovir (United States)
2014

U-M Rogel Cancer Center
2003-2013

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. Developing minimally invasive techniques that can diagnose NSCLC, particularly at an early stage, may improve its outcome. Using microarray platforms, we previously identified 12 microRNAs (miRNAs) aberrant expressions which in primary tumors are associated with early-stage NSCLC. Here, extend our previous research by investigating whether miRNAs could be used as potential plasma biomarkers for We initially...

10.1038/labinvest.2010.194 article EN cc-by-nc-sa Laboratory Investigation 2010-11-29

Abstract Adenocarcinoma is the most common type of lung cancer, leading cause cancer deaths in world. Early detection key to improve survival adenocarcinoma patients. We have previously shown that microRNAs (miRNAs) were stably present sputum and could be applied diagnosis cancer. The aim our study was develop a panel miRNAs can used as highly sensitive specific markers for early adenocarcinoma. Our contained 3 phases: ( i ) marker discovery using miRNA profiling on paired normal tumor...

10.1002/ijc.25289 article EN International Journal of Cancer 2010-03-02

10.1006/jmva.2001.2017 article EN publisher-specific-oa Journal of Multivariate Analysis 2002-07-01

Despite the role of aerobic glycolysis in cancer, recent studies highlight importance mitochondria and biosynthetic pathways as well. PPARγ coactivator 1α (PGC1α) is a key transcriptional regulator several metabolic including oxidative metabolism lipogenesis. Initial suggested that PGC1α expression reduced tumors compared with adjacent normal tissue. Paradoxically, other show associated cancer cell proliferation. Therefore, especially carcinogenesis unclear. Using Pgc1α(-/-) Pgc1α(+/+) mice,...

10.1158/0008-5472.can-11-1011 article EN Cancer Research 2011-09-14

To assist the development and application of blood-contacting medical devices, two novel flow-through Couette-type blood-shearing devices have been developed to study quantitative relationship between blood damage indexes flow-dependent parameters. One device is an axial supported by a pair pin bearings adapted from adult Jarvik 2000 pump. The other centrifugal with magnetic CentriMag In both rotor spindle was used replace original impeller blades so that small gap created housing rotating...

10.1111/j.1525-1594.2011.01243.x article EN Artificial Organs 2011-08-02

Myeloma-directed cellular immune responses after autologous stem cell transplantation (ASCT) may reduce relapse rates. We studied whether coinjecting the TLR-3 agonist and vaccine adjuvant Poly-ICLC with a MAGE-A3 peptide was safe would elicit high frequency of vaccine-directed when combined vaccine-primed costimulated T cells.In phase II clinical trial (NCT01245673), we evaluated safety activity ex vivo expanded cells primed in using multipeptide (compound GL-0817) (Hiltonol), granulocyte...

10.1158/1078-0432.ccr-13-2817 article EN Clinical Cancer Research 2014-02-12

ABSTRACT There is insufficient information about combination therapy with approved anti-influenza agents. We tested combinations that paired a neuraminidase (NA) inhibitor (zanamivir, oseltamivir carboxylate, or peramivir) rimantadine against infection of MDCK cells H1N1 and H3N2 subtypes influenza A virus characterized their mode interaction. When reduction extracellular was analyzed by individual regression models three-dimensional representations the data, all three showed additive...

10.1128/aac.48.12.4855-4863.2004 article EN Antimicrobial Agents and Chemotherapy 2004-11-24

Abstract We previously reported that our novel compound 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (VN/124-1) is a potent 17α-hydroxylase/17,20-lyase (CYP17) inhibitor/antiandrogen and strongly inhibits the formation proliferation of human prostate cancer LAPC4 tumor xenografts in severe combined immunodeficient mice. In this study, we report VN/124-1 other CYP17 inhibitors also cause down-regulation androgen receptor (AR) protein expression vitro vivo. This mechanism action...

10.1158/1535-7163.mct-08-0230 article EN Molecular Cancer Therapeutics 2008-08-01

Previously, we showed that adoptive transfer of in vivo vaccine-primed and ex (anti-CD3/anti-CD28) costimulated autologous T cells (ex-T) at day +12 after transplant increased CD4 CD8 T-cell counts +42 augmented vaccine-specific immune responses patients with myeloma. Here, investigated the safety kinetics recovery infusing ex-T +2 transplant.In this phase I/II two-arm clinical trial, 50 myeloma received autografts high-dose melphalan followed by infusions transplant. Patients also...

10.1158/1078-0432.ccr-09-0418 article EN Clinical Cancer Research 2009-06-10

// Jian Su 1,* , Jeipi Liao Lu Gao Jun Shen Maria A. Guarnera 1 Min Zhan 2 HongBin Fang Sanford Stass and Feng Jiang Department of Pathology, University Maryland School Medicine, Baltimore, MD, USA Epidemiology Public Health, * These authors have contributed equally to this work Correspondence to: Jiang, email: Keywords : lung cancer, sputum, biomarkers, snoRNAs, diagnosis Received April 15, 2014 Accepted May 09, 2015 Published 20, Abstract Molecular analysis sputum presents a noninvasive...

10.18632/oncotarget.4219 article EN Oncotarget 2015-05-20

Abnormal microRNA (miRNA) expressions and promoter methylation of genes detected in sputum may provide biomarkers for non-small lung cancer (NSCLC). Here, we evaluate the individual combined analysis two classes molecular NSCLC detection. We analyze expression 3 miRNAs (miR-21, miR-31, miR-210) (RASSF1A, PRDM14, 3OST2), which were previously identified as potential NSCLC, a set 117 stage I patients 174 cancer-free smokers. The results are validated different 144 171 controls. panel miRNA has...

10.1186/s13148-016-0275-5 article EN cc-by Clinical Epigenetics 2016-10-19

Structure-based drug repositioning in addition to random chemical screening is now a viable route rapid development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important cancer, especially both BRAFWT BRAFV600E. We find MBZ synergizes the MEK inhibitor trametinib inhibit growth of BRAFWT-NRASQ61K melanoma cells culture xenografts, markedly decreased ERK phosphorylation. Reverse Phase Protein Array (RPPA)...

10.18632/oncotarget.14990 article EN Oncotarget 2017-02-02

The early detection of lung cancer continues to be a major clinical challenge. Using whole-transcriptome next-generation sequencing analyze tumor and the matched noncancerous tissues, we previously identified 54 cancer-associated microRNAs (miRNAs). objective this study was investigate whether miRNAs could used as plasma biomarkers for cancer. We determined expressions tumor-miRNAs in development cohort 180 subjects by using reverse transcription PCR develop biomarkers. included 92 patients...

10.18632/oncotarget.22950 article EN Oncotarget 2017-12-05

Abstract. We consider large sample inference in a semiparametric logistic/proportional-hazards mixture model. This model has been proposed to survival data where there exists positive portion of subjects the population who are not susceptible event under consideration. Previous studies have focused on developing point estimation procedures for unknown parameters. paper inferences based maximum likelihood estimator. Specifically, we establish existence, consistency and asymptotic normality...

10.1111/j.1467-9469.2005.00415.x article EN Scandinavian Journal of Statistics 2005-02-17

To determine the maximum-tolerated dose (MTD) of histone deacetylase inhibitor vorinostat combined with fixed doses cytarabine (ara-C or cytosine arabinoside) and etoposide in patients poor-risk advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, vivo pharmacodynamic effects leukemia blasts.In this open-label phase I study, was given orally on days one seven at three escalating levels: 200 mg twice a day, times 300 day. On 11 14, (100 mg/m(2)) (1 2 g/m(2)...

10.1158/1078-0432.ccr-12-3165 article EN Clinical Cancer Research 2013-02-13

To evaluate the function and substrate specificity of human breast cancer resistance protein (BCRP, ABCG2) in absence cofactors or heterologous partner proteins, <i>Xenopus laevis</i> oocytes were injected with cRNA wild-type mutant (R482T) BCRP. High expression BCRP was observed on oocyte surface. Accumulation efflux assays revealed that expressing R482T transported daunorubicin (DNR), mitoxantrone (MX), rhodamine 123, flavopiridol (FLV), whereas only MX FLV, agreement observations...

10.1124/mol.64.6.1452 article EN Molecular Pharmacology 2003-11-26
Coming Soon ...